keyword
MENU ▼
Read by QxMD icon Read
search

ziv-aflibercept

keyword
https://www.readbyqxmd.com/read/29103187/real-world-treatment-patterns-and-effectiveness-among-patients-with-metastatic-colorectal-cancer-treated-with-ziv-aflibercept-in-community-oncology-practices-in-the-usa
#1
Jasmina I Ivanova, Kimberly R Saverno, Jennifer Sung, Mei Sheng Duh, Chen Zhao, Sean Cai, Francis Vekeman, Aaron Peevyhouse, Ravinder Dhawan, Charles S Fuchs
Routine clinical practice data often differ from clinical trials. This study describes real-world treatment patterns and effectiveness among patients with metastatic colorectal cancer (mCRC) receiving ziv-aflibercept in non-academic, community oncology practices in the USA. De-identified electronic medical records from Vector Oncology and Altos Solutions databases were analysed. We identified 218 patients diagnosed with mCRC who had received prior oxaliplatin therapy and initiated ziv-aflibercept as part of second-line or later-line therapy...
November 4, 2017: Medical Oncology
https://www.readbyqxmd.com/read/29021377/a-comprehensive-review-of-sequencing-and-combination-strategies-of-targeted-agents-in-metastatic-colorectal-cancer
#2
REVIEW
Kristen K Ciombor, Tanios Bekaii-Saab
The emergence of targeted therapies for the treatment of metastatic colorectal cancer (mCRC) has considerably improved survival, but has resulted in a dilemma of identifying the optimal sequence and combination of various agents in the mCRC treatment landscape. A number of cytotoxic agents, including irinotecan, oxaliplatin, 5-fluorouracil, capecitabine, and TAS-102, are available for treatment of mCRC. Additionally, whereas patients harboring rat sarcoma viral oncogene homolog (RAS)-wild type mCRC can be treated with the anti-epidermal growth factor receptor antibodies cetuximab and panitumumab or antiangiogenic agents (bevacizumab, ziv-aflibercept, and ramucirumab), patients with RAS-mutant mCRC are limited to antiangiogenic agents as biologic options...
October 11, 2017: Oncologist
https://www.readbyqxmd.com/read/28971631/intravitreal-ziv-aflibercept-clinical-effects-and-economic-impact
#3
Sumit Randhir Singh, Avantika Dogra, Michael Stewart, Taraprasad Das, Jay Chhablani
During the past decade, drugs that inhibit the actions of vascular endothelial growth factor (VEGF) have become standard-of-care treatment for a variety of chorioretinal vascular conditions. The off-label, intravitreal use of ziv-aflibercept (Zaltrap) has provided clinicians with an additional cost-effective drug. The commercial preparation of ziv-aflibercept contains the same aflibercept (VEGF-trap) molecule as Eylea but has a much higher osmolarity (1000 mOsm/kg vs 300 mOsm/kg). Initial concerns regarding cytotoxicity and long-term safety of intravitreal ziv-aflibercept have been largely negated after a series of publications failed to identify adverse ocular and systemic side effects...
October 3, 2017: Asia-Pacific Journal of Ophthalmology
https://www.readbyqxmd.com/read/28913517/intravitreal-injection-of-ziv-aflibercept-in-the-treatment-of-choroidal-and-retinal-vascular-diseases
#4
Kamran HodjatJalali, Shiva Mehravaran, Hooshang Faghihi, Hassan Hashemi, Pegah Kazemi, Hadith Rastad
PURPOSE: To investigate the short-term outcomes after intravitreal injection of ziv-aflibercept in the treatment of choroidal and retinal vascular diseases. METHODS: Thirty-four eyes of 29 patients with age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion (RVO) received a single dose intravitreal injection of 0.05 ml ziv-aflibercept (1.25 mg). Visual acuity, spectral domain optical coherence tomography (SD-OCT) activity, and possible side effects were assessed before and at 1 week and 1 month after the intervention...
September 2017: Journal of Current Ophthalmology
https://www.readbyqxmd.com/read/28807738/observed-benefit-and-safety-of-aflibercept-in-elderly-patients-with-metastatic-colorectal-cancer-an-age-based-analysis-from-the-randomized-placebo-controlled-phase-iii-velour-trial
#5
Paul Ruff, Eric Van Cutsem, Radek Lakomy, Jana Prausova, Guy A van Hazel, Vladimir M Moiseyenko, Karen Soussan-Lazard, Emmanuelle Dochy, Emmanuelle Magherini, Teresa Macarulla, Demetris Papamichael
OBJECTIVES: Aflibercept (ziv-aflibercept) significantly improves progression-free (PFS) and overall survival (OS) when added to 5-fluorouracil, leucovorin and irinotecan (FOLFIRI), compared with FOLFIRI alone, in patients with metastatic colorectal cancer previously treated with oxaliplatin-based therapy. This subset analysis of the VELOUR study investigates aflibercept plus FOLFIRI versus placebo plus FOLFIRI according to age. METHODS: Efficacy and safety were analyzed by treatment arm and age (≥ or <65years)...
August 12, 2017: Journal of Geriatric Oncology
https://www.readbyqxmd.com/read/28792245/a-phase-2-study-of-5-fluorouracil-5-fu-ziv-aflibercept-and-radiation-for-the-preoperative-and-adjuvant-treatment-of-patients-with-stage-ii-iii-rectal-cancer
#6
MULTICENTER STUDY
Johanna C Bendell, Dana Thompson, Brian M Hemphill, David Wenk, Chris Earwood, Cassie M Lane, Andrew Kennedy
BACKGROUND: This phase II study combined aflibercept with preoperative chemoradiation for patients with stage II/III rectal cancer, followed by mFOLFOX6/aflibercept. METHODS: Patients received preoperative 5-FU (days 1-43), radiation (weeks 1-6), and aflibercept (days 1-15) each 28 day cycle for 6 weeks. Six weeks following the last aflibercept dose, patients underwent surgical resection. Four cycles of mFOLFOX6 plus aflibercept began 8 weeks after surgery. RESULTS: Common treatment-related toxicities included diarrhea, fatigue, and mucositis...
September 14, 2017: Cancer Investigation
https://www.readbyqxmd.com/read/28736761/phase-ii-study-of-dovitinib-in-patients-progressing-on-anti-vascular-endothelial-growth-factor-therapy
#7
Thomas J Semrad, Edward J Kim, Michael S Tanaka, Jacob Sands, Chris Roberts, Rebekah A Burich, Yu Li, David R Gandara, Primo Lara, Philip C Mack
BACKGROUND: Prior work identified the fibroblast growth factor (FGF) pathway as a mediator of resistance to anti-vascular endothelial growth factor (VEGF) therapy. We tested dovitinib, an inhibitor of both FGF and VEGF receptors, in patients progressing on anti-VEGF treatment. METHODS: Patients with measurable advanced colorectal or non-small cell lung cancer with progression despite anti-VEGF treatment within 56 days, good performance status and adequate organ function were eligible...
2017: Cancer Treat Res Commun
https://www.readbyqxmd.com/read/28712102/precision-medicine-in-metastatic-colorectal-cancer-relevant-carcinogenic-pathways-and-targets-part-2-approaches-beyond-first-line-therapy-and-novel-biologic-agents-under-investigation
#8
REVIEW
Benjamin A Weinberg, Marion L Hartley, Mohamed E Salem
A frequent quandary for oncologists is the selection of chemotherapy and biologic therapy for patients with metastatic colorectal cancer in second-line and higher treatment settings. While not approved by the US Food and Drug Administration (FDA) in the first-line setting, the vascular endothelial growth factor (VEGF)-targeting agents ziv-aflibercept and ramucirumab are appropriate treatment options in the second-line setting, as is continuation of first-line bevacizumab. Tumor RAS mutational status is helpful to determine which patients may benefit from epidermal growth factor receptor (EGFR)-directed therapies, and other novel biomarkers (BRAF, HER2, and mismatch repair deficiency) allow us to select patients who may benefit from biologic therapies that are FDA-approved for other malignancies...
July 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28712098/precision-medicine-in-metastatic-colorectal-cancer-relevant-carcinogenic-pathways-and-targets-part-1-biologic-therapies-targeting-the-epidermal-growth-factor-receptor-and-vascular-endothelial-growth-factor
#9
REVIEW
Benjamin A Weinberg, Marion L Hartley, Mohamed E Salem
The survival of patients with metastatic colorectal cancer has improved dramatically in recent years, with overall survival exceeding 3 years in large randomized clinical trials. There are now several treatment options for patients with metastatic colorectal cancer. In addition to chemotherapy backbones utilizing fluoropyrimidine, oxaliplatin, and irinotecan combinations, biologic agents that target specific oncogenic pathways have contributed to the improved survival observed in this patient population. This class of medications includes epidermal growth factor receptor (EGFR)-targeted drugs (cetuximab and panitumumab) and vascular endothelial growth factor (VEGF)-targeted therapies (bevacizumab, ramucirumab, ziv-aflibercept, and regorafenib)...
July 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28652928/ph-of-anti-vegf-agents-in-the-human-vitreous-low-impact-of-very-different-formulations
#10
Bianka Sobolewska, Peter Heiduschka, Karl-Ulrich Bartz-Schmidt, Focke Ziemssen
BACKGROUND: The aim of the study was to measure pH changes of the human vitreous caused by the intravitreal drugs bevacizumab, ranibizumab, aflibercept, and ziv-aflibercept. METHODS: Fresh human vitreous samples were obtained during core vitrectomy (23-gauge) from patients with epiretinal gliosis. Aliquots of bevacizumab, ranibizumab, aflibercept or ziv-aflibercept (2 µl) were added consecutively to 200 µl of vitreous samples or 0.9% NaCl saline. The pH was measured using a pH-sensitive microelectrode...
2017: International Journal of Retina and Vitreous
https://www.readbyqxmd.com/read/28614154/regression-of-inflamed-pterygia-by-frequent-high-dose-intralesional-ziv-aflibercept
#11
Ahmad M Mansour
PURPOSE: Intralesional single low-dose vascular endothelial growth factor antagonists have traditionally failed in causing regression of pterygia. The current pilot study investigates the role of high-dose repeated intralesional ziv-aflibercept in causing regression of inflamed or recurring pterygia. METHODS: This prospective study from January 2015 to April 2017 consisted of using high dose of ziv-aflibercept between 0.1 mL (2.5 mg) and 0.3 mL (7.5 mg), depending on the pterygium size and the degree of inflammation...
June 13, 2017: Cornea
https://www.readbyqxmd.com/read/28596286/one-year-outcome-of-intravitreal-ziv-aflibercept-therapy-for-non-responsive-neovascular-age-related-macular-degeneration
#12
Imoro Zeba Braimah, Komal Agarwal, Ahmad Mansour, Jay Chhablani
AIM: To evaluate 12-month outcome of intravitreal ziv-aflibercept (IVZ) therapy in eyes with neovascular age-related macular degeneration (nAMD) that are non-responsive to bevacizumab and ranibizumab. METHODS: This retrospective study included 16 eyes (14 patients) with nAMD who were on prior treatment with bevacizumab and ranibizumab and were treated with as-needed IVZ (1.25 mg/0.05 mL) for 12 months. The primary outcome measure was the mean change in best corrected visual acuity (BCVA) and secondary outcome measures included mean change in central macular thickness (CMT), retinal pigment epithelial detachment (RPED) heights, longest treatment free interval, presence of subretinal fluid (SRF) and intraretinal fluid (IRF) and adverse events...
June 8, 2017: British Journal of Ophthalmology
https://www.readbyqxmd.com/read/28548650/aflibercept-in-age-related-macular-degeneration-evaluating-its-role-as-a-primary-therapeutic-option
#13
REVIEW
M Ashraf, A A R Souka
The recent VIEW studies have demonstrated the non-inferiority of monthly and bi-monthly aflibercept in the management of wet age related macular degeneration (AMD) compared with ranibizumab. However, the current data are limited mainly to fixed dosing regimens with few studies looking at flexible dosing regimens of aflibercept in wet AMD. In addition, recent data from the VIEW 96 week extension has shown that patients being shifted from fixed dosing regimens to PRN have shown a drop in visual acuity and increase in central macular thickness...
November 2017: Eye
https://www.readbyqxmd.com/read/28499051/safety-and-efficacy-of-ziv-aflibercept-in-the-treatment-of-refractory-diabetic-macular-edema
#14
Mohammed Ashraf, Hassan El Kayal, Ahmed A R Souka
BACKGROUND AND OBJECTIVE: To evaluate the safety and efficacy of ziv-aflibercept (Zaltrap; Sanofi-Aventis, Bridgewater, NJ/Regeneron Pharmaceuticals, Tarrytown, NY) in the treatment of refractory diabetic macular edema (DME). PATIENTS AND METHODS: Retrospective case series looking at the safety of ziv-aflibercept in patients with DME refractory to previous anti-vascular endothelial growth factor (VEGF) therapy. Detailed ophthalmologic examination, best-corrected visual acuity, and optical coherence tomography measurements were performed pre-switch, as well as at each monthly follow-up visit...
May 1, 2017: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/28280634/erratum-to-osteonecrosis-of-the-jaw-associated-with-ziv-aflibercept
#15
(no author information available yet)
[This corrects the article on p. E81 in vol. 7, PMID: 28078129.].
February 2017: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/28270485/long-term-safety-and-efficacy-of-ziv-aflibercept-in-retinal-diseases
#16
Ahmad M Mansour, Mohammed Ashraf, Chintan J Dedhia, Abdulrazzak Charbaji, Ahmed A R Souka, Jay Chhablani
AIMS: To investigate the long-term safety of intravitreal ziv-aflibercept in eyes receiving six or more intravitreal injections of ziv-aflibercept, an off-label substitute to the approved aflibercept. METHODS: Consecutive patients with retinal disease receiving six or more of intravitreal 0.05 mL ziv-aflibercept (1.25 mg) injections were followed monthly in three centres. Outcome measures were best-corrected visual acuity (BCVA) (logarithm of the minimum angle of resolution (logMar)) and central macular thickness (CMT) on spectral domain optical coherence tomography and monitoring for ocular inflammation, progression of lens opacities and intraocular pressure rise...
October 2017: British Journal of Ophthalmology
https://www.readbyqxmd.com/read/28138259/advances-in-antiangiogenic-treatment-of-small-cell-lung-cancer
#17
REVIEW
Hongyang Lu, Zhiming Jiang
Small-cell lung cancer (SCLC), a poorly differentiated neuroendocrine malignancy, has a rapid growth rate, strong aggressiveness, early metastases, and poor prognosis. Angiogenesis greatly contributes to the metastatic process of SCLC, which has a higher vascularization compared with non-small-cell lung cancer (NSCLC). SCLC might constitute an ideal malignancy for assessing new antiangiogenic drugs and therapeutic strategies. Combining bevacizumab with paclitaxel has therapeutic benefits in chemoresistant, relapsed SCLC...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28119292/intravitreal-ziv-aflibercept-for-the-treatment-of-choroidal-neovascularisation-associated-with-conditions-other-than-age-related-macular-degeneration
#18
Imoro Zeba Braimah, Michael Stewart, Chetan Videkar, Chintan J Dedhia, Jay Chhablani
AIM: To report the short-term outcomes of eyes with choroidal neovascularisation (CNV) associated with causes other than age-related macular degeneration (AMD) after treatment with intravitreal ziv-aflibercept (IVZ) injections. METHODS: This retrospective study included eyes with non-AMD-related CNV that were treated with IVZ (1.25 mg/0.05 mL) on a pro re nata basis. The primary outcome measure is the mean change in best-corrected visual acuity (BCVA) and secondary outcome measures include the mean change in central macular thickness (CMT) and adverse events...
September 2017: British Journal of Ophthalmology
https://www.readbyqxmd.com/read/28078129/osteonecrosis-of-the-jaw-associated-with-ziv-aflibercept
#19
Hani Mawardi, Peter Enzinger, Nadine McCleary, Reshma Manon, Alessandro Villa, Nathaniel Treister, Sook-Bin Woo
Medication-related osteonecrosis of the jaw (MRONJ) has been associated with medications that include bisphosphonates (BPs), denosumab, bevacizumab and sunitinib. Ziv-aflibercept is a recombinant human vascular endothelial growth factor (VEGF) receptor which has been used to treat patients with various advanced solid tumors. We report three patients without a history of the use of medications known to cause MRONJ presenting with jaw osteonecrosis typical for MRONJ following therapy with ziv-aflibercept. All patients had metastatic gastrointestinal cancer treated with ziv-aflibercept and were evaluated for MRONJ because of exposed bone in the oral cavity...
December 2016: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/28060148/short-term-safety-of-2-mg-intravitreal-ziv-aflibercept
#20
Jay Chhablani, Chintan Jethalal Dedhia, Hari K Peguda, Michael Stewart
PURPOSE: To evaluate the safety of single intravitreal 2 mg ziv-aflibercept (0.08 mL) injections for the treatment of choroidal neovascular membranes (CNVM). METHODS: Eyes with choroidal neovascular membranes because of several conditions each received single intravitreal injections of 2 mg ziv-aflibercept (0.08 mL). Comprehensive ophthalmic examinations and detailed systemic evaluations were performed at baseline and Days 1, 7, and 30 after injections. Standard electroretinography was performed at baseline and Day 30...
October 2017: Retina
keyword
keyword
66937
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"